Tran le
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,559, more than ten times the $122 reported in 2022. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$598
- Bayer$549
- Amgen$445
- AbbVie$445
- Novo Nordisk$392
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,903100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,133 |
| GSK | 36 | $598 |
| Bayer | 42 | $549 |
| Amgen | 29 | $445 |
| AbbVie | 43 | $445 |
| Novo Nordisk | 18 | $392 |
| Sumitomo Pharma America, Inc. | 15 | $254 |
| Gilead | 2 | $244 |
| Lilly USA, LLC | 11 | $200 |
| Axsome Therapeutics, Inc. | 7 | $173 |
| Boehringer Ingelheim | 8 | $131 |
| Scilex Pharmaceuticals Inc. | 4 | $76 |
| Exact Sciences | 4 | $67 |
| Pfizer | 3 | $46 |
| Ardelyx, Inc. | 2 | $40 |
| Lundbeck LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,903 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 234 | $115,932 |
| RybelsusSemaglutide | 54 | $93,849 |
| GemtesaVibegron | 104 | $77,864 |
| JardianceEmpagliflozin | 63 | $65,957 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 39 | $54,349 |
| JanuviaSitagliptin Phosphate | 38 | $50,823 |
| FarxigaDapagliflozin Propanediol | 42 | $49,395 |
| GlyxambiEmpagliflozin/Linagliptin | 39 | $43,100 |
| LinzessLinaclotide | 46 | $40,330 |
| TradjentaLinagliptin | 35 | $37,004 |
| RestasisCyclosporine | 50 | $36,379 |
| CreonLipase/Protease/Amylase | 16 | $33,522 |
| XareltoRivaroxaban | 19 | $32,070 |
| OzempicSemaglutide | 20 | $28,573 |
| VemlidyTenofovir Alafenamide | 16 | $22,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta | $131 | $200,410176 claims |
| Novo NordiskRybelsus, Ozempic | $392 | $122,42274 claims |
| AbbVieLinzess, Restasis, Creon | $445 | $110,231112 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $254 | $77,864104 claims |
| AstraZenecaFarxiga | $1,133 | $49,39542 claims |
| GileadVemlidy | $244 | $22,68716 claims |
| PfizerEliquis | $46 | $12,65615 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $76 | $8,94515 claims |
| GSKTrelegy Ellipta | $598 | $7,72512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Katy
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.